Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 533

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

A Randomized Trial of Itraconazole in Allergic Bronchopulmonary Aspergillosis

Open access
Stevens, David A., Schwartz, Howard J., Lee, Jeannette Y., Moskovitz, Bruce L., Jerome, Dennis C., Catanzaro, Antonino, Bamberger, David M., Weinmann, Allison J., Tuazon, Carmelita U., Judson, Marc A., Platts-Mills, Thomas A.E., Grossman, Jay, Slavin, Raymond G., Reuman, Peter, DeGraff, Arthur C.·2000·New England Journal of Medicine

Abstract

BACKGROUND: Allergic bronchopulmonary aspergillosis is a hypersensitivity disorder that can progress from an acute phase to chronic disease. The main treatment is systemic corticosteroids, but data from uncontrolled studies suggest that itraconazole, an orally administered antifungal agent, may be an effective adjunctive therapy. METHODS: We conducted a randomized, double-blind trial of treatment with either 200 mg of itraconazole twice daily or placebo for 16 weeks in patients who met immunologic and pulmonary-function criteria for corticosteroid-dependent allergic bronchopulmonary aspergillosis. A response was defined as a reduction of at least 50 percent in the corticosteroid dose, a decrease of at least 25 percent in the serum IgE concentration, and one of the following: an improvement of at least 25 percent in exercise tolerance or pulmonary-function tests or resolution or absence of pulmonary infiltrates. In a second, open-label part of the trial, all the patients received 200 mg of itraconazole per day for 16 weeks. RESULTS: There were responses in 13 of 28 patients in the itraconazole group (46 percent), as compared with 5 of 27 patients in the placebo group (19 percent, P=0.04). The rate of adverse events was similar in the two groups. In the subsequent open-label phase, 12 of the 33 patients who had not had a response during the double-blind phase (36 percent) had responses, and none of the patients who had a response in the double-blind phase of the trial had a relapse. CONCLUSIONS: For patients with corticosteroid-dependent allergic bronchopulmonary aspergillosis, the addition of itraconazole can lead to improvement in the condition without added toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm200003163421102

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 533

Metadata

Authors
Stevens, D. A., Schwartz, H. J., Lee, J. Y., Moskovitz, B. L., Jerome, D. C., Catanzaro, A., Bamberger, D. M., Weinmann, A. J., Tuazon, C. U., Judson, M. A., Platts-Mills, T. A. E., Grossman, J., Slavin, R. G., Reuman, P., & DeGraff, A. C.
Venue
New England Journal of Medicine
Published
2000-03-16
Volume
342
Issue
11
Pages
756-762
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W1974893215
Cited by
533
References
36
FWCI
13.42
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Randomized Trial of Itraconazole in Allergic Bronchopulmonary Aspergillosis. https://app.cochat.ai/papers/10.1056/nejm200003163421102
The paper
Stevens, D. A., Schwartz, H. J., Lee, J. Y., Moskovitz, B. L., Jerome, D. C., Catanzaro, A., Bamberger, D. M., Weinmann, A. J., Tuazon, C. U., Judson, M. A., Platts-Mills, T. A. E., Grossman, J., Slavin, R. G., Reuman, P., & DeGraff, A. C. (2000). A Randomized Trial of Itraconazole in Allergic Bronchopulmonary Aspergillosis. New England Journal of Medicine. https://doi.org/10.1056/nejm200003163421102

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.